Palliative Care Clinical Trials

Our team is dedicated to clinical research in the field of palliative care. For more information on any of these trials, or to find out if you're eligible to participate, contact Carolyn Revta, Palliative Care Clinical Research Operations Director, or 858-822-3614.

Ongoing Studies

Alliance A221303: Randomized Study of Early Palliative Care Integrated with Standard Oncology Care versus Standard Oncology Care Alone in Patients with Incurable Lung or Non-Colorectal Gastrointestinal Malignancies

Status: Currently recruiting
Eligible: Patients and family caregivers of patients with incurable lung or non-colorectal gastrointestinal cancer
Patients diagnosed with metastatic cancer are known to benefit from palliative care in an inpatient setting however, the impact of palliative care in the outpatient setting is not known. Outpatient palliative care may serve to improve quality of life, increase understanding of the disease process, and decrease rates of depression in the population of patients and caregivers who receive this type of care. This randomized, controlled trial serves to compare outcomes of patients receiving early outpatient palliative care along with standard oncology care vs. patients receiving standard oncology care alone. Patients recently diagnosed with stage IV non-colorectal gastrointestinal or lung cancers may be eligible for this study. Those randomized to the early palliative care intervention will be asked to participate in monthly palliative care visits provided by a board certified palliative care physician and/or nurse practitioner which may take place in clinic, in the infusion center, or via phone.

Single Center, Prospective Expansion Study Evaluating Advance Care Planning Discussions Utilizing the 3 Questions

Status: Currently recruiting
Eligible: Advanced Stage Cancer Patients
Given the limited prognosis of advanced cancer patients, understanding and effectively communicating their end-of-life wishes is critical. These discussions should occur in the non-emergent outpatient setting when cancer patients may effectively communicate their wishes. However, social and pragmatic barriers limit advance care planning discussions. This study evaluates one simple, non-threatening innovative approach to address advance care planning using a tool developed by the Doris A. Howell Palliative Care Service called the 3 Questions. The 3 Questions are designed to help patients express their desires for advanced care and successfully identify an informed health care proxy or durable power of attorney. The goal of this study is to determine the proportion of advanced cancer patients who identify a health care proxy following implementation of the 3 Questions when administered by a Howell Service medical provider.

Positive Support in Cancer Care: Emphasizing Quality of Life and Legacy

Status: Currently recruiting
Eligible: Cancer patients who are eligible for or are currently receiving hospice or palliative care
This study focuses on the positive outcomes of providing cancer patients with extra support and attention. Patients included in this study will receive extra support from trained clinicians over the course of approximately two weeks. There will be two groups in the study. One group will be focused on support through storytelling and the creation of a life story (legacy) document. The second group will be focused on general support for daily needs or concerns. The primary goal of this study will help researchers understand the impact of different types of psychosocial support and how this process may positively impact people's well-being and quality of life.

SWOG S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride

Status: Currently recruiting identifier: NCT01416688
Eligible: Patients with a diagnosis of colorectal or lung cancer planning to receive HER1/EGFR therapy
There are a group of drugs called EGFR inhibitors (cetuximab, panitumumab and erlotinib) that often cause rash and other skin problems. Doctors and nurses need to record how severe they are in order to know whether to lower the dose. Doctors and nurses use a widely accepted grading tool that describes signs and symptoms associated with the rash and assigns a number to the rash in order of severity to evaluate the rash. However, descriptions in the grading tool do not always match what the doctors and nurses see in their examinations. A new questionnaire (FACT-EGFR 18) was developed to allow patients to rate, from their point of view, how severe their skin toxicities are and how these symptoms affect their quality of life. The questionnaire has to be used by several patients who are being treated with these drugs in order to show that the questionnaire can measure skin symptoms in a reliable manner. The purpose of this study is to have patients on these kinds of drugs who experience skin side effects when taking EGFR inhibitors, provide information about their skin symptoms through the FACT-EGFR 18 questionnaire, to see if it can be used as a reliable tool along with the usual grading tool to better manage side effects caused by these drugs. Eligible patients include those diagnosed with colorectal or lung cancers planning to receive certain HER/EGFR inhibitor therapies for at least 6 weeks. During this study, patients will be asked to fill out questionnaires rating the extent to which the patient experiences skin related side effects. These questionnaires will be completed weekly for 6 weeks and then monthly for 3 months. Participation in this trial will not prohibit participation in other clinical trials at Moores Cancer Center.

Vector Oncology ALSSCINV1305: Observational Study of CINV in Patients Receiving Multiday Highly Emetogenic Chemotherapy Regimens for Hematological Malignancies

Status: Currently Recruiting
Eligible: Patients receiving multiday highly-emetogenic chemotherapy for blood cancers
Chemotherapy induced nausea and vomiting (CINV) can have an impact on the quality of life of patients with cancer. This is especially true for patients going through treatments with chemotherapy agents with a higher likelihood to cause vomiting (highly-emetogenic), such as combination treatments including cytarabine, anthracyclines, cyclophosphamide, fludarabine, clofarabine, and idarubicin that patients may receive to treat blood cancers. Several different medications are available to lessen or prevent CINV. These medications are called antiemetics and are given to patients before and/or after cancer treatment. The purpose of this study is to collect information about medications that are currently being prescribed to you by your doctor to lessen or prevent CINV and patient response to that treatment. Patients receiving blood cancer treatment over several days with drugs that have a high risk of causing CINV are eligible to participate. Patients will be asked to complete questionnaires during regularly-scheduled treatment visits and by telephone during participation in the study. Participation in this trial will not prohibit participation in other clinical trials at Moores Cancer Center.


Carolyn Revta
Palliative Care Clinical Research Operations Director
Moores Cancer Center
Phone: 858-822-3614